DK3386541T3 - Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab - Google Patents
Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab Download PDFInfo
- Publication number
- DK3386541T3 DK3386541T3 DK16818985.0T DK16818985T DK3386541T3 DK 3386541 T3 DK3386541 T3 DK 3386541T3 DK 16818985 T DK16818985 T DK 16818985T DK 3386541 T3 DK3386541 T3 DK 3386541T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical formulation
- aqueous pharmaceutical
- including anti
- formulation including
- antibody avelumab
- Prior art date
Links
- 229950002916 avelumab Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15198233 | 2015-12-07 | ||
| PCT/EP2016/002040 WO2017097407A1 (en) | 2015-12-07 | 2016-12-05 | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3386541T3 true DK3386541T3 (da) | 2020-09-28 |
Family
ID=54838201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16818985.0T DK3386541T3 (da) | 2015-12-07 | 2016-12-05 | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US11058769B2 (da) |
| EP (2) | EP3747466A1 (da) |
| JP (1) | JP6925337B2 (da) |
| KR (1) | KR102697026B1 (da) |
| CN (1) | CN108367072B (da) |
| AR (1) | AR107014A1 (da) |
| AU (1) | AU2016368099C1 (da) |
| BR (1) | BR112018010211A2 (da) |
| CA (1) | CA3007481C (da) |
| CL (1) | CL2018001488A1 (da) |
| CO (1) | CO2018005525A2 (da) |
| CY (1) | CY1123358T1 (da) |
| DK (1) | DK3386541T3 (da) |
| EA (1) | EA201891339A1 (da) |
| ES (1) | ES2823279T3 (da) |
| HR (1) | HRP20201573T1 (da) |
| HU (1) | HUE050811T2 (da) |
| IL (1) | IL259563B (da) |
| LT (1) | LT3386541T (da) |
| MX (1) | MX389289B (da) |
| MY (1) | MY195681A (da) |
| NZ (1) | NZ743964A (da) |
| PE (1) | PE20181400A1 (da) |
| PH (1) | PH12018500894A1 (da) |
| PL (1) | PL3386541T3 (da) |
| PT (1) | PT3386541T (da) |
| RS (1) | RS61029B1 (da) |
| SA (1) | SA518391743B1 (da) |
| SG (1) | SG11201804758QA (da) |
| SI (1) | SI3386541T1 (da) |
| SM (1) | SMT202000497T1 (da) |
| TW (1) | TWI630917B (da) |
| UA (1) | UA123270C2 (da) |
| WO (1) | WO2017097407A1 (da) |
| ZA (1) | ZA201804534B (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2785375T (lt) * | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CA2936962C (en) | 2014-03-14 | 2024-03-05 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| CA2960824A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| CA2964367C (en) | 2014-10-14 | 2024-01-30 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| JP6826055B2 (ja) | 2015-03-13 | 2021-02-03 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| BR112018010211A2 (pt) | 2015-12-07 | 2019-02-05 | Merck Patent Gmbh | formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab |
| SG11201811003PA (en) | 2016-06-13 | 2019-01-30 | I Mab | Anti-pd-l1 antibodies and uses thereof |
| IL265762B2 (en) | 2016-10-06 | 2024-04-01 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| MX2019010367A (es) * | 2017-03-06 | 2019-12-02 | Merck Patent Gmbh | Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1). |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| US12150990B2 (en) | 2017-11-02 | 2024-11-26 | Nanjing Shunxin Pharmaceutical Co., Ltd. | Pharmaceutical composition of humanized monoclonal anti-PD-L1 antibody |
| CA3189025A1 (en) * | 2017-12-22 | 2019-06-27 | Samsung Bioepis Co., Ltd. | Liquid composition comprising vegf antagonist |
| CN118852460A (zh) * | 2017-12-28 | 2024-10-29 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) |
| WO2020020307A1 (en) | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| WO2020060183A1 (ko) * | 2018-09-18 | 2020-03-26 | 삼성바이오에피스 주식회사 | 트라스투주맙 항체 안정화 액체 제제 |
| WO2020108497A1 (zh) * | 2018-11-29 | 2020-06-04 | 和铂医药（香港）有限公司 | 一种抗pd-l1抗体制剂 |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| BR112021026414A2 (pt) * | 2019-06-25 | 2022-04-12 | Innovent Biologics Suzhou Co Ltd | Formulação compreendendo o anticorpo biespecífico anti-cd47/pd-l1, método para preparo e uso do mesmo |
| CN111420049A (zh) * | 2019-08-22 | 2020-07-17 | Biocad股份公司 | 抗-pd1抗体prolgolimab的水性药物组合物及其应用 |
| US12121565B2 (en) | 2019-09-13 | 2024-10-22 | Duke University | Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies |
| US12380963B2 (en) | 2019-10-14 | 2025-08-05 | The Medical College Of Wisconsin, Inc. | Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy |
| WO2021091964A1 (en) | 2019-11-04 | 2021-05-14 | Duke University | Treatment for primary and metastatic cancer |
| EP4074338A4 (en) * | 2019-12-13 | 2024-03-06 | Samsung Bioepis Co., Ltd. | PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODY |
| CN115298218A (zh) * | 2019-12-18 | 2022-11-04 | 特沙诺有限公司 | 生物药物组合物和相关方法 |
| KR102683876B1 (ko) * | 2020-11-11 | 2024-07-11 | 가톨릭대학교 산학협력단 | 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트 |
| EP4362984A1 (en) | 2021-07-02 | 2024-05-08 | Yale University | Compositions and methods for treating cancers |
| WO2023034864A1 (en) | 2021-08-31 | 2023-03-09 | Yale University | Compositions and methods for treating cancers |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US7728117B2 (en) | 2005-09-02 | 2010-06-01 | Glycomimetics, Inc. | Heterobifunctional pan-selectin inhibitors |
| KR101378194B1 (ko) * | 2005-12-20 | 2014-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | 안정한 단백질 제제 |
| WO2009126556A1 (en) | 2008-04-08 | 2009-10-15 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
| US8217149B2 (en) * | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| CA2783715A1 (en) * | 2009-12-29 | 2011-07-07 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
| US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
| AU2012236479B2 (en) * | 2011-03-31 | 2016-10-20 | Merck Sharp & Dohme Llc | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| LT2785375T (lt) * | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
| MY164611A (en) | 2012-01-23 | 2018-01-30 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| PT3049441T (pt) | 2013-09-27 | 2020-01-21 | Hoffmann La Roche | Formulações de anticorpos anti-pdl1 |
| WO2015057910A1 (en) * | 2013-10-16 | 2015-04-23 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| CA2949121A1 (en) * | 2014-05-15 | 2015-11-19 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| CN105085680A (zh) * | 2014-05-23 | 2015-11-25 | 复旦大学 | 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用 |
| SG10201810615VA (en) | 2015-02-26 | 2019-01-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| WO2016181348A1 (en) | 2015-05-14 | 2016-11-17 | Pfizer Inc. | Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body |
| JP2018518483A (ja) | 2015-06-08 | 2018-07-12 | ジェネンテック， インコーポレイテッド | 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法 |
| US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
| JP2018529719A (ja) | 2015-09-30 | 2018-10-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ |
| BR112018010211A2 (pt) | 2015-12-07 | 2019-02-05 | Merck Patent Gmbh | formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab |
| MX2019010367A (es) | 2017-03-06 | 2019-12-02 | Merck Patent Gmbh | Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1). |
-
2016
- 2016-12-05 BR BR112018010211-3A patent/BR112018010211A2/pt active IP Right Grant
- 2016-12-05 PE PE2018001077A patent/PE20181400A1/es unknown
- 2016-12-05 JP JP2018529213A patent/JP6925337B2/ja active Active
- 2016-12-05 SI SI201630940T patent/SI3386541T1/sl unknown
- 2016-12-05 ES ES16818985T patent/ES2823279T3/es active Active
- 2016-12-05 UA UAA201807363A patent/UA123270C2/uk unknown
- 2016-12-05 PT PT168189850T patent/PT3386541T/pt unknown
- 2016-12-05 LT LTEP16818985.0T patent/LT3386541T/lt unknown
- 2016-12-05 HR HRP20201573TT patent/HRP20201573T1/hr unknown
- 2016-12-05 EA EA201891339A patent/EA201891339A1/ru unknown
- 2016-12-05 EP EP20184113.7A patent/EP3747466A1/en not_active Withdrawn
- 2016-12-05 CN CN201680071740.1A patent/CN108367072B/zh active Active
- 2016-12-05 KR KR1020187019480A patent/KR102697026B1/ko active Active
- 2016-12-05 RS RS20201201A patent/RS61029B1/sr unknown
- 2016-12-05 WO PCT/EP2016/002040 patent/WO2017097407A1/en not_active Ceased
- 2016-12-05 AU AU2016368099A patent/AU2016368099C1/en active Active
- 2016-12-05 US US16/060,319 patent/US11058769B2/en active Active
- 2016-12-05 MY MYPI2018702171A patent/MY195681A/en unknown
- 2016-12-05 PL PL16818985T patent/PL3386541T3/pl unknown
- 2016-12-05 SG SG11201804758QA patent/SG11201804758QA/en unknown
- 2016-12-05 EP EP16818985.0A patent/EP3386541B1/en active Active
- 2016-12-05 HU HUE16818985A patent/HUE050811T2/hu unknown
- 2016-12-05 MX MX2018006875A patent/MX389289B/es unknown
- 2016-12-05 SM SM20200497T patent/SMT202000497T1/it unknown
- 2016-12-05 CA CA3007481A patent/CA3007481C/en active Active
- 2016-12-05 DK DK16818985.0T patent/DK3386541T3/da active
- 2016-12-05 NZ NZ743964A patent/NZ743964A/en unknown
- 2016-12-06 TW TW105140288A patent/TWI630917B/zh active
- 2016-12-07 AR ARP160103760A patent/AR107014A1/es not_active Application Discontinuation
-
2018
- 2018-04-26 PH PH12018500894A patent/PH12018500894A1/en unknown
- 2018-05-23 IL IL259563A patent/IL259563B/en active IP Right Grant
- 2018-05-25 CO CONC2018/0005525A patent/CO2018005525A2/es unknown
- 2018-06-04 CL CL2018001488A patent/CL2018001488A1/es unknown
- 2018-06-06 SA SA518391743A patent/SA518391743B1/ar unknown
- 2018-07-06 ZA ZA201804534A patent/ZA201804534B/en unknown
-
2020
- 2020-09-24 CY CY20201100904T patent/CY1123358T1/el unknown
- 2020-12-09 US US17/116,587 patent/US20210100903A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3386541T3 (da) | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab | |
| IL282304A (en) | Topical pharmaceutical compositions | |
| FR25C1022I1 (fr) | Anticorps anti-pd-1 | |
| JP2018536676A5 (ja) | 抗ｐｄ−ｌ１抗体アベルマブを含む水性医薬製剤 | |
| EP3334824A4 (en) | PD-1 ANTIBODY | |
| SI4070787T1 (sl) | Farmacevtske formulacije | |
| EP3383915A4 (en) | PD-1 ANTIBODY | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| DK3199161T3 (da) | Farmaceutisk præparat | |
| EP3603642A4 (en) | PHARMACEUTICAL PREPARATION | |
| DK3256154T3 (da) | Farmaceutisk formulering omfattende antistof | |
| EP3383371C0 (en) | PHARMACEUTICAL FORMULATION | |
| EP3646866A4 (en) | PHARMACEUTICAL PREPARATION | |
| DK3280447T3 (da) | Farmaceutiske formuleringer | |
| EP3337463A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| HUE069648T2 (hu) | Gyógyszerészeti készítmény | |
| EP3498839A4 (en) | Anti-pd-1 antibody | |
| DK3463365T3 (da) | Farmaceutisk antifungal formulering | |
| DK3247394T3 (da) | Farmaceutisk formulering omfattende anti-egfr-antistof | |
| EP3305294A4 (en) | AQUEOUS MEDICINE | |
| DK3601277T3 (da) | Farmaceutisk formulering | |
| DK3288967T3 (da) | Farmaceutisk forbindelse | |
| HUE050881T2 (hu) | Gyógyszerkészítmény | |
| EP3305295A4 (en) | AQUEOUS MEDICINE |